WS

Warren Shawn Carbonell

Chief Scientific Officer at OncoSynergy

Redondo Beach, California

Overview 

Warren Shawn Carbonell is a highly accomplished Scientist and Founder, currently serving as the Chief Scientific Officer at OncoSynergy and the Co-founder & CEO of Brazen Bio. He has made significant contributions in the fields of cancer research and biotechnology, with a strong background in oncology and neurodegeneration. Carbonell's career highlights include founding Cure Glioblastoma and Brazen Bio, along with holding leadership roles at OncoSynergy and conducting postdoctoral research at prestigious institutions like University of Oxford and UCSF.

Work Experience 

O

OncoSynergy

  • Chief Scientific Officer

    2022 - Current

OncoSynergy improves outcomes for patients with unmet needs in oncology with resistance mechanism inhibitors.

Raised $23,256,575.00 from Connecticut Innovations, NLabs and Korea Information & Communication Co..

oncosynergy.com
BC

Brazen Capital

  • Cofounder & Managing Partner

    2021

    Academia sucks. Start a startup. Funding the rising generation of scientist-CEOs.

Brazen Capital is a venture capital fund.

brazen.capital
BB

Brazen Bio

  • Cofounder & CEO

    2021

    Building community for the rising generation of scientist-CEOs

Brazen Bio helps scientists spin their research out of labs and into the private markets.

brazen.bio
CG

Cure Glioblastoma

  • Cofounder & President

    2019

    Building awareness and solutions for brain cancer.

O

OncoSynergy

  • Cofounder & CEO

    2011 - 2019

    Inventor and developer of the first ever clinical stage beta1 integrin therapeutic, OS2966.

OncoSynergy improves outcomes for patients with unmet needs in oncology with resistance mechanism inhibitors.

Raised $23,256,575.00 from Connecticut Innovations, NLabs and Korea Information & Communication Co..

oncosynergy.com
U

UCSF

  • Postdoctoral Scholar, Department of Neurological Surgery

    2010 - 2012

    Studied the role of CD29 in driving therapy resistance in glioblastoma, @Brain Tumor Research Center (BTRC)

Uo

University of Oxford

  • Nicholas Kurti Junior Fellow in Science

    2007 - 2010

    Demonstrated the key role of CD29 in the establishment and progression of brain metastases.

  • Senior Postdoctoral Fellow

    2006 - 2009

    Senior Postdoctoral Researcher supported by Cancer Research UK. Established and was a lead investigator of the brain metastasis research program in the Department of Radiation Oncology and Biology at the University of Oxford, UK.

CM

Cedars-Sinai Medical Center

  • Neurosurgery Resident

    2009 - 2009

Cedars-Sinai Health Ventures is a venture capital firm.

cedarssinaihv.com

University of Virginia School of Medicine

  • Medical Student (MSTP)

    1999 - 2006

    Dean's Merit Scholar of the Medical Scientist Training Program (MD/PhD).

  • Graduate Researcher (MSTP)

    2000 - 2005

    PhD student in the Department of Neuroscience through the UVA Medical Scientist Training Program (MSTP). Research focus: neuroinflammation in disease states and injury. Analysis of cell migration in the brain.

Uo

University of Washington

  • Undergraduate Researcher

    1995 - 1999

    Researcher in the Department of Neurological Surgery. Research focus: traumatic brain injury.

Education 

Articles About Warren Shawn

Relevant Websites